FDA Clears Dexcom's First OTC Glucose Monitor for Type 2 Diabetes

Stelo, designed for non-insulin type 2 diabetes patients, aims to enhance access to glucose monitoring, set to launch this summer.

Dexcom's Stelo, the first over-the-counter glucose monitor, receives FDA clearance, targeting type 2 diabetes patients not on insulin.
Stelo is designed to be paired with a smartphone, providing continuous glucose monitoring without a prescription.
The device, expected to be available this summer, aims to improve access to glucose monitoring for about 25 million Americans.
Stelo's launch is anticipated to make glucose monitoring more accessible, especially for those without CGM insurance coverage.
Shares of Dexcom surged over 8% following the announcement, highlighting the market's positive reception.